Clinical outcomes in Graves

Yamina Aribi; kablia Samia Ould; Lila Brakni; Lamia Hadjres; Meriem Koli; Samir Ait Abderahmane; Fateh Bentayeb; Zoubir Sellal; Meriem Bensaleh; Zahra Kemali; Reda Nacer Khodja; Meriem Medjaher; E M Haffaf

doi:10.1530/endoabs.32.P1039

P1039

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P1039 | DOI: 10.1530/endoabs.32.P1039

ECE2013 Poster Presentations Thyroid (non-cancer) (100 abstracts)

Clinical outcomes in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine

Yamina Aribi ¹ , Samia Ould kablia ¹ , Lila Brakni ¹ , Lamia Hadjres ¹ , Meriem Koli ¹ , Samir Ait Abderahmane ¹ , Fateh Bentayeb ¹ , Zoubir Sellal ¹ , Meriem Bensaleh ¹ , Zahra Kemali ¹ , Reda Nacer Khodja ² , Meriem Medjaher ² & E M Haffaf ²

Err

Author affiliations

¹Department of Endocrinology, Central Hospital of the Army, Algiers, Algeria; ²Department of Nuclear Medicine, Central Hospital of the Army, Algiers, Algeria.

The most common cause of hyperthyroidism in young patients is Graves’ disease (GD). It is an auto immune disorder caused by TSH-receptor-stimulating auto antibodies.

Treatment options for GD include anti-thyroid drugs (ATD), radioactive iodine (RAI), and surgery. The treatment modalities used vary in different parts of the world.

Objectives: To compare the effect of different treatment and to determine the profile of patients who undergo such and such a treatment modalities outcome.

Methods: A retrospective study between 2007 and 2012 at the central hospital of the army. 100 GD patients were included and received different treatment.

Results: We treated 100 patients (63 men and 37 women) the average age was 33 years. 42 patients received ATD, 17 patients randomized to surgery, and 35 patients were treated with RAI. Subjects were followed for mean of 31 months (range, 1–69 months) for the following clinical outcomes: 73% of patients treated by ATD experienced persistent/recurrent hyperthyroidism. 100% of patients who undergo surgery became free of disease after total thyroidectomy without recurrence. Complication rate was 18%. 81% were successfully treated (hypothyroid or euthyroid) after a single dose of RAI with no acute complication.

Conclusion: In our opinion the medical therapy (ATD: 24 months) is not a very performed therapy in our country taking into account our socioeconomic context. Thyroidectomy can be performed with low complication rates and there is no risk of recurrence if total thyroidectomy is performed. But not indicated for all patients. The RAI is a safe and effective treatment for GD. It is relatively inexpensive. For our young military patients it is the ideal therapy for a speedy recovery with no acute complication.